1-Butyloxy-4-Methoxybenzene

1-Butyloxy-4-Methoxybenzene

SCHEMBL1047291

CCCCOc1ccc(OC)cc1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.61
LTA4H P09960 4/20 0.59
NR5A1 Q13285 1/20 0.57
MAPT P10636 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
HPGD P15428 1/20 0.56
ATM Q13315 1/20 0.56
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA7 P43166 2/20 0.55
CA9 Q16790 2/20 0.55
CA14 Q9ULX7 1/20 0.55
DRD2 P14416 1/20 0.55
DRD4 P21917 1/20 0.55
DRD3 P35462 1/20 0.55
TSHR P16473 1/20 0.53
KCNH2 Q12809 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1-Methoxy-4-Pentoxybenzene SCHEMBL7778996 0.95 NR5A1 (0.64) AHRLTA4HNR5A1MAPTL3MBTL1
SCHEMBL13042288 0.93 NR5A1 (0.68) AHRLTA4HNR5A1MAPTL3MBTL1
SCHEMBL13110618 0.93 NR5A1 (0.68) AHRLTA4HNR5A1MAPTL3MBTL1
SCHEMBL11983233 0.93 NR5A1 (0.68) AHRLTA4HNR5A1MAPTL3MBTL1
SCHEMBL2095782 0.93 NR5A1 (0.68) AHRLTA4HNR5A1MAPTL3MBTL1
SCHEMBL23128627 0.93 NR5A1 (0.68) AHRLTA4HNR5A1MAPTL3MBTL1
SCHEMBL2951017 0.93 NR5A1 (0.68) AHRLTA4HNR5A1MAPTL3MBTL1
1-Methoxy-4-Propoxybenzene SCHEMBL1324557 0.90 LTA4H (0.57) AHRLTA4HMAPTL3MBTL1HPGD
SCHEMBL8434882 0.90 CA12 (0.61) MAPTL3MBTL1HPGDATMCA12
SCHEMBL9808262 0.90 MAPT (0.62) MAPTL3MBTL1HPGDATMCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118359513-A Chain oxamide ligand and application thereof in copper-catalyzed C-O coupling reaction 广东工业大学 2024-07-19 CN disclosed
CN-117957123-A Thermosensitive recording medium 王子控股株式会社 2024-04-30 CN disclosed
CN-116490375-A Thermosensitive recording medium 王子控股株式会社 2023-07-25 CN disclosed
US-11000515-B2 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease SHY Therapeutics LLC (US) 2021-05-11 US disclosed
EP-3394056-B1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2021-04-14 EP disclosed
US-20200061037-A1 COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, INC. 2020-02-27 US disclosed
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 WO disclosed
US-20150336925-A1 SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2015-11-26 US disclosed
US-20150224099-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OTSUKA PHARMA CO LTD (JP) 2015-08-13 US disclosed
US-8987304-B2 Antituberculous composition comprising oxazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
EP-1223809-A4 METHODS OF TREATING HAIR LOSS COMPRISING ADMINISTERING INDOLINE COMPOUND UNIV TEXAS SOUTHWESTERN MED CT (US) 2004-03-03 EP disclosed
WO-2003007954-A2 SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2003-01-30 WO disclosed
EP-1223809-A1 METHODS OF TREATING HAIR LOSS COMPRISING ADMINISTERING INDOLINE COMPOUND UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2002-07-24 EP disclosed
WO-2001030151-A1 METHODS OF TREATING HAIR LOSS COMPRISING ADMINISTERING INDOLINE COMPOUND THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2001-05-03 WO disclosed
EP-0087248-B2 LIQUID CRYSTAL COMPOSITION CONTAINING AZO DYES MITSUBISHI KASEI CORPORATION (JP) 1989-02-08 EP disclosed
US-4737310-A PLEOCHROIC MITSUBISHI CHEMICAL INDUSTRIES (JP) 1988-04-12 US disclosed
US-4600527-A AZO DYES, MULT&COLOR, PHOTOCHROMIC MITSUBISHI CHEMICAL INDUSTRIES (JP) 1986-07-15 US disclosed
EP-0087248-B1 LIQUID CRYSTAL COMPOSITION CONTAINING AZO DYES MITSUBISHI KASEI CORPORATION (JP) 1986-05-28 EP disclosed
US-4404354-A FROM P-DIALKOXYBENZENES, HEAT RESISTANT DAINIPPON INK AND CHEMICALS, INC. (JP) 1983-09-13 US disclosed
EP-0087248-A1 Liquid crystal composition containing azo dyes MITSUBISHI KASEI CORPORATION (JP) 1983-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150224099-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 AHR 1203/4885LTA4H 813/4885NR5A1 1910/4885
US-11000515-B2 Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease HRAS, KRAS, NRAS AHR 2195/4885LTA4H 1542/4885NR5A1 2466/4885
US-20150336925-A1 SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCLAF1 AHR 219/4885LTA4H 3823/4885NR5A1 3973/4885
US-20200061037-A1 COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE HRAS, KRAS, NRAS AHR 2195/4885LTA4H 1542/4885NR5A1 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.